Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sue Robinson

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
British Journal of Haematology|May 27, 2024
Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDPDouglas A Stewart, John Kuruvilla, David Lee, et al.
British Journal of Haematology|January 20, 2007
A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7Chaim Shustik, Andrew Belch, Sue Robinson, et al.
Blood Advances|July 22, 2018
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)John C Byrd, Amy S Ruppert, Nyla A Heerema, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 TrialRanjana H Advani, Fangxin Hong, Richard I Fisher, et al.
Blood|March 23, 2017
Venetoclax and obinutuzumab in chronic lymphocytic leukemiaKirsten Fischer, Othman Al-Sawaf, Anna-Maria Fink, et al.
The Lancet. Oncology|September 5, 2020
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialOthman Al-Sawaf, Can Zhang, Maneesh Tandon, et al.
The New England Journal of Medicine|June 6, 2019
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ConditionsKirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, et al.
Lancet (London, England)|July 29, 2014
Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trialMarc A Rodger, William M Hague, John Kingdom, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
British Journal of Haematology|May 27, 2024
Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDPDouglas A Stewart, John Kuruvilla, David Lee, et al.
British Journal of Haematology|January 20, 2007
A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7Chaim Shustik, Andrew Belch, Sue Robinson, et al.
Blood Advances|July 22, 2018
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)John C Byrd, Amy S Ruppert, Nyla A Heerema, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 TrialRanjana H Advani, Fangxin Hong, Richard I Fisher, et al.
Blood|March 23, 2017
Venetoclax and obinutuzumab in chronic lymphocytic leukemiaKirsten Fischer, Othman Al-Sawaf, Anna-Maria Fink, et al.
The Lancet. Oncology|September 5, 2020
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialOthman Al-Sawaf, Can Zhang, Maneesh Tandon, et al.
The New England Journal of Medicine|June 6, 2019
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ConditionsKirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, et al.
Lancet (London, England)|July 29, 2014
Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trialMarc A Rodger, William M Hague, John Kingdom, et al.
Pageof 5